Mouse models of hepatitis B and delta virus infection

Journal of Immunological Methods

Volumn 410, Issue , 2014, Pages 39-49

  Dandri, Maura ^a,b   Lütgehetmann, Marc ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b German Center for Infection Research   (Germany)

Author keywords

Human liver chimeric mice; Preclinical HBV HDV infection studies; Transgenic mice

Indexed keywords

ADENOVIRUS VECTOR; DNA DIRECTED RNA POLYMERASE; HEPATITIS B ANTIGEN; HEPATITIS DELTA ANTIGEN; SINGLE STRANDED RNA; VIRUS RNA;

ACUTE HEPATITIS; DELTA AGENT HEPATITIS; HEPATITIS B; HUMAN; HYDRODYNAMICS; HYDRODYNAMICS BASED TRANSFECTION; IMMUNE RESPONSE; LIVER CELL; LIVER CELL DAMAGE; MIXED INFECTION; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; TRANSGENIC MOUSE; VIRAL CLEARANCE; VIRION; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; ARTICLE; DIET THERAPY; DISEASE MODEL; DRUG EFFECT; FEMALE; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HOST PATHOGEN INTERACTION; HUMAN LIVER CHIMERIC MICE; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRECLINICAL HBV/HDV INFECTION STUDIES; VIROLOGY;

HUMAN LIVER CHIMERIC MICE; PRECLINICAL HBV/HDV INFECTION STUDIES; TRANSGENIC MICE;

ANIMALS; COINFECTION; DISEASE MODELS, ANIMAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; MICE; VIRUS REPLICATION;

EID: 84908509378     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.03.002     Document Type: Review

References (94)

1. Allweiss L., et al. Proliferation of hepatitis B virus infected human hepatocytes induces suppression of viral replication and rapid cccDNA decrease in humanized mice. April 2013. J. Hepatol. April 2013, 58(Suppl.1):S56-S57.
2. Allweiss L., Volz T., Lutgehetmann M., Giersch K., Bornscheuer T., Lohse A.W., Petersen J., Ma H., Klumpp K., Fletcher S.P., Dandri M. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J. Hepatol. 2014, 60:500-507.
3. Araki K., Miyazaki J., Hino O., Tomita N., Chisaka O., Matsubara K., Yamamura K. Expression and replication of hepatitis B virus genome in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:207-211.
4. -/- mice. Nat. Biotechnol. 2007, 25:903-910.
5. Baumert T.F., Yang C., Schurmann P., Kock J., Ziegler C., Grullich C., Nassal M., Liang T.J., Blum H.E., von Weizsacker F. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary tupaia hepatocytes. Hepatology 2005, 41:247-256.
6. Belloni L., Allweiss L., Guerrieri F., Pediconi N., Volz T., Pollicino T., Petersen J., Raimondo G., Dandri M., Levrero M. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J. Clin. Invest. 2012, 122:529-537.
7. Bissig K.D., Le T.T., Woods N.B., Verma I.M. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20507-20511.
8. Bissig K.D., Wieland S.F., Tran P., Isogawa M., Le T.T., Chisari F.V., Verma I.M. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Invest. 2010, 120:924-930.
9. Bocher W.O., Galun E., Marcus H., Daudi N., Terkieltaub D., Shouval D., Lohr H.F., Reisner Y. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse [in process citation]. Hepatology 2000, 31:480-487.
10. Bordier B.B., Ohkanda J., Liu P., Lee S.Y., Salazar F.H., Marion P.L., Ohashi K., Meuse L., Kay M.A., Casey J.L., Sebti S.M., Hamilton A.D., Glenn J.S. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J. Clin. Invest. 2003, 112:407-414.
11. Brezillon N.M., DaSilva L., L'Hote D., Bernex F., Piquet J., Binart N., Morosan S., Kremsdorf D. Rescue of fertility in homozygous mice for the urokinase plasminogen activator transgene by the transplantation of mouse hepatocytes. Cell Transplant. 2008, 17:803-812.
12. Brezillon N., Brunelle M.N., Massinet H., Giang E., Lamant C., DaSilva L., Berissi S., Belghiti J., Hannoun L., Puerstinger G., Wimmer E., Neyts J., Hantz O., Soussan P., Morosan S., Kremsdorf D. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One 2011, 6:e25096.
13. Chang J., Sigal L.J., Lerro A., Taylor J. Replication of the human hepatitis delta virus genome Is initiated in mouse hepatocytes following intravenous injection of naked DNA or RNA sequences. J. Virol. 2001, 75:3469-3473.
14. Chisari F.V., Pinkert C.A., Milich D.R., Filippi P., McLachlan A., Palmiter R.D., Brinster R.L. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985, 230:1157-1160.
15. Dandri M., Petersen J. Chimeric mouse model of hepatitis B virus infection. J. Hepatol. 2012, 56:493-495.
16. Dandri M., Schirmacher P., Rogler C.E. Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication. J. Virol. 1996, 70:5246-5254.
17. Dandri M., Burda M.R., Gocht A., Torok E., Pollok J.M., Rogler C.E., Will H., Petersen J. Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation. Hepatology 2001, 34:824-833.
18. Dandri M., Burda M.R., Torok E., Pollok J.M., Iwanska A., Sommer G., Rogiers X., Rogler C.E., Gupta S., Will H., Greten H., Petersen J. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001, 33:981-988.
19. Dandri M., Burda M.R., Zuckerman D.M., Wursthorn K., Matschl U., Pollok J.M., Rogiers X., Gocht A., Kock J., Blum H.E., von Weizsacker F., Petersen J. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J. Hepatol. 2005, 42:54-60.
20. Ebert G., Poeck H., Lucifora J., Baschuk N., Esser K., Esposito I., Hartmann G., Protzer U. 5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology 2011, 141:696-706. (706 e1-3.).
21. Eren R., Ilan E., Nussbaum O., Lubin I., Terkieltaub D., Arazi Y., Ben-Moshe O., Kitchinzky A., Berr S., Gopher J., Zauberman A., Galun E., Shouval D., Daudi N., Eid A., Jurim O., Magnius L.O., Hammas B., Reisner Y., Dagan S. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 2000, 32:588-596.
22. Giersch K., Helbig M., Volz T., Allweiss L., Mancke L.V., Lohse A.W., Polywka S., Pollok J.M., Petersen J., Taylor J., Dandri M., Lutgehetmann M. Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. J Hepatol. 2014 Mar 2014 Mar, 60(3):538-544.
23. Grompe M., al-Dhalimy M., Finegold M., Ou C.N., Burlingame T., Kennaway N.G., Soriano P. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev. 1993, 7:2298-2307.
24. Guidotti L.G., Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 2006, 1:23-61.
25. Guidotti L.G., Guilhot S., Chisari F.V. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J. Virol. 1994, 68:1265-1270.
26. Guidotti L.G., Matzke B., Schaller H., Chisari F.V. High-level hepatitis B virus replication in transgenic mice. J. Virol. 1995, 69:6158-6169.
27. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:25-36.
28. Guidotti L.G., Matzke B., Pasquinelli C., Schoenberger J.M., Rogler C.E., Chisari F.V. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J. Virol. 1996, 70:7056-7061.
29. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
30. Gutti T.L., Knibbe J.S., Makarov E., Zhang J., Yannam G.R., Gorantla S., Sun Y., Mercer D.F., Suemizu H., Wisecarver J.L., Osna N.A., Bronich T.K., Poluektova L.Y. Human hepatocytes and hematolymphoid dual reconstitution in treosulfan-conditioned uPA-NOG mice. Am. J. Pathol. 2014, 184:101-109.
31. Hasegawa M., Kawai K., Mitsui T., Taniguchi K., Monnai M., Wakui M., Ito M., Suematsu M., Peltz G., Nakamura M., Suemizu H. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem. Biophys. Res. Commun. 2011, 405:405-410.
32. Heise T., Guidotti L.G., Cavanaugh V.J., Chisari F.V. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J. Virol. 1999, 73:474-481.
33. Hiraga N., Imamura M., Hatakeyama T., Kitamura S., Mitsui F., Tanaka S., Tsuge M., Takahashi S., Abe H., Maekawa T., Ochi H., Tateno C., Yoshizato K., Wakita T., Chayama K. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J. Hepatol. 2009, 51:1046-1054.
34. Hughes S.A., Wedemeyer H., Harrison P.M. Hepatitis delta virus. Lancet 2011 Jul 2, 378(9785):73-85.
35. Ilan E., Burakova T., Dagan S., Nussbaum O., Lubin I., Eren R., Ben-Moshe O., Arazi J., Berr S., Neville L., Yuen L., Mansour T.S., Gillard J., Eid A., Jurim O., Shouval D., Reisner Y., Galun E. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 1999, 29:553-562.
36. Isogawa M., Kakimi K., Kamamoto H., Protzer U., Chisari F.V. Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology 2005, 333:293-300.
37. Julander J.G., Sidwell R.W., Morrey J.D. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antivir. Res. 2002, 55:27-40.
38. Julander J.G., Colonno R.J., Sidwell R.W., Morrey J.D. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Antivir. Res. 2003, 59:155-161.
39. Katoh M., Sawada T., Soeno Y., Nakajima M., Tateno C., Yoshizato K., Yokoi T. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J. Pharm. Sci. 2007, 96:428-437.
40. Kim C.M., Koike K., Saito I., Miyamura T., Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351:317-320.
41. Klein C., Bock C.T., Wedemeyer H., Wustefeld T., Locarnini S., Dienes H.P., Kubicka S., Manns M.P., Trautwein C. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003, 125:9-18.
42. Kosaka K., Hiraga N., Imamura M., Yoshimi S., Murakami E., Nakahara T., Honda Y., Ono A., Kawaoka T., Tsuge M., Abe H., Hayes C.N., Miki D., Aikata H., Ochi H., Ishida Y., Tateno C., Yoshizato K., Sasaki T., Chayama K. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections. Biochem. Biophys. Res. Commun. 2013, 441:230-235.
43. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., Gastaminza P., Chisari F.V., Jones I.M., Fox R.I., Ball J.K., McKeating J.A., Kneteman N.M., Burton D.R. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 2008, 14:25-27.
44. Li H., Zhuang Q., Wang Y., Zhang T., Zhao J., Zhang Y., Zhang J., Lin Y., Yuan Q., Xia N., Han J. HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. Cell Mol. Immunol. 2014 Mar, 11(2):175-183.
45. Lin Y.J., Huang L.R., Yang H.C., Tzeng H.T., Hsu P.N., Wu H.L., Chen P.J., Chen D.S. Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9340-9345.
46. Lutgehetmann M., Volz T., Kopke A., Broja T., Tigges E., Lohse A.W., Fuchs E., Murray J.M., Petersen J., Dandri M. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010, 52:16-24.
47. Lutgehetmann M., Bornscheuer T., Volz T., Allweiss L., Bockmann J.H., Pollok J.M., Lohse A.W., Petersen J., Dandri M. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 2011, 140:2074-2083. (2083 e1-2).
48. Lutgehetmann M., Mancke L.V., Volz T., Helbig M., Allweiss L., Bornscheuer T., Pollok J.M., Lohse A.W., Petersen J., Urban S., Dandri M. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 2012, 55:685-694.
49. Mason W.S., Seal G., Summers J. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J. Virol. 1980, 36:829-836.
50. Mason W.S., Aldrich C., Summers J., Taylor J.M. Asymmetric replication of duck hepatitis B virus DNA in liver cells: free minus-strand DNA. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:3997-4001.
51. Mason W.S., Jilbert A.R., Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1139-1144.
52. McCaffrey A.P., Nakai H., Pandey K., Huang Z., Salazar F.H., Xu H., Wieland S.F., Marion P.L., Kay M.A. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 2003, 21:639-644.
53. Mederacke I., Filmann N., Yurdaydin C., Bremer B., Puls F., Zacher B.J., Heidrich B., Tillmann H.L., Rosenau J., Bock C.T., Savas B., Helfritz F., Lehner F., Strassburg C.P., Klempnauer J., Wursthorn K., Lehmann U., Manns M.P., Herrmann E., Wedemeyer H. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J. Hepatol. 2012, 56:115-122.
54. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R., Tyrrell D.L., Kneteman N.M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 2001, 7:927-933.
55. Meuleman P., Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antivir. Res. 2008, 80:231-238.
56. Meuleman P., Catanese M.T., Verhoye L., Desombere I., Farhoudi A., Jones C.T., Sheahan T., Grzyb K., Cortese R., Rice C.M., Leroux-Roels G., Nicosia A. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012, 55:364-372.
57. Moriyama T., Guilhot S., Klopchin K., Moss B., Pinkert C.A., Palmiter R.D., Brinster R.L., Kanagawa O., Chisari F.V. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990, 248:361-364.
58. Nakagawa S., Hirata Y., Kameyama T., Tokunaga Y., Nishito Y., Hirabayashi K., Yano J., Ochiya T., Tateno C., Tanaka Y., Mizokami M., Tsukiyama-Kohara K., Inoue K., Yoshiba M., Takaoka A., Kohara M. Targeted induction of interferon-lambda in humanized chimeric mouse liver abrogates hepatotropic virus infection. PLoS One 2013, 8:e59611.
59. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008, 134:235-249.
60. Nkongolo S., Ni Y., Lempp F.A., Kaufman C., Lindner T., Esser-Nobis K., Lohmann V., Mier W., Mehrle S., Urban S. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J. Hepatol. 2013, (Epub ahead of print). 10.1016/j.jhep.2013.11.022.
61. Ohira M., Ishiyama K., Tanaka Y., Doskali M., Igarashi Y., Tashiro H., Hiraga N., Imamura M., Sakamoto N., Asahara T., Chayama K., Ohdan H. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J. Clin. Invest. 2009, 119:3226-3235.
62. Okamoto Y., Shinjo K., Shimizu Y., Sano T., Yamao K., Gao W., Fujii M., Osada H., Sekido Y., Murakami S., Tanaka Y., Joh T., Sato S., Takahashi S., Wakita T., Zhu J., Issa J.P., Kondo Y. Hepatitis virus infection affects DNA methylation in mice with humanized livers. Gastroenterology 2014, 146:562-572.
63. Okazaki A., Hiraga N., Imamura M., Hayes C.N., Tsuge M., Takahashi S., Aikata H., Abe H., Miki D., Ochi H., Tateno C., Yoshizato K., Ohdan H., Chayama K. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. Hepatology 2012, 56:555-566.
64. Petersen J., Dandri M., Gupta S., Rogler C.E. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:310-315.
65. Petersen J., Dandri M., Mier W., Lutgehetmann M., Volz T., von Weizsacker F., Haberkorn U., Fischer L., Pollok J.M., Erbes B., Seitz S., Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 2008, 26:335-341.
66. Raney A.K., Eggers C.M., Kline E.F., Guidotti L.G., Pontoglio M., Yaniv M., McLachlan A. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. J. Virol. 2001, 75:2900-2911.
67. Rhim J.A., Sandgren E.P., Degen J.L., Palmiter R.D., Brinster R.L. Replacement of diseased mouse liver by hepatic cell transplantation. Science 1994, 263:1149-1152.
68. Rhim J.A., Sandgren E.P., Palmiter R.D., Brinster R.L. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:4942-4946.
69. Rizzetto M. Hepatitis D: thirty years after. J. Hepatol. 2009, 50:1043-1050.
70. Roggendorf M., Tolle T.K. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 1995, 38:100-112.
71. Samuel D., Zignego A.L., Reynes M., Feray C., Arulnaden J.L., David M.F., Gigou M., Bismuth A., Mathieu D., Gentilini P., et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995, 21:333-339.
72. Sandgren E.P., Palmiter R.D., Heckel J.L., Daugherty C.C., Brinster R.L., Degen J.L. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991, 66:245-256.
73. Sitia G., Isogawa M., Iannacone M., Campbell I.L., Chisari F.V., Guidotti L.G. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J. Clin. Invest. 2004, 113:1158-1167.
74. Slagle B.L., Lee T.H., Medina D., Finegold M.J., Butel J.S. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol. Carcinog. 1996, 15:261-269.
75. Song X., Guo Y., Duo S., Che J., Wu C., Ochiya T., Ding M., Deng H. A mouse model of inducible liver injury caused by tet-on regulated urokinase for studies of hepatocyte transplantation. Am. J. Pathol. 2009, 175:1975-1983.
76. Sprinzl M.F., Oberwinkler H., Schaller H., Protzer U. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. J. Virol. 2001, 75:5108-5118.
77. Summers J., Mason W.S. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:638-640.
78. Sureau C. The role of the HBV envelope proteins in the HDV replication cycle. Curr. Top. Microbiol. Immunol. 2006, 307:113-131.
79. Tateno C., Yoshizane Y., Saito N., Kataoka M., Utoh R., Yamasaki C., Tachibana A., Soeno Y., Asahina K., Hino H., Asahara T., Yokoi T., Furukawa T., Yoshizato K. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 2004, 165:901-912.
80. Tesfaye A., Stift J., Maric D., Cui Q., Dienes H.P., Feinstone S.M. Chimeric mouse model for the infection of hepatitis B and C viruses. PLoS One 2013, 8:e77298.
81. Tsuge M., Hiraga N., Takaishi H., Noguchi C., Oga H., Imamura M., Takahashi S., Iwao E., Fujimoto Y., Ochi H., Chayama K., Tateno C., Yoshizato K. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005, 42:1046-1054.
82. Tsuge M., Hiraga N., Akiyama R., Tanaka S., Matsushita M., Mitsui F., Abe H., Kitamura S., Hatakeyama T., Kimura T., Miki D., Mori N., Imamura M., Takahashi S., Hayes C.N., Chayama K. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. J. Gen. Virol. 2010, 91:1854-1864.
83. Volz T., Lutgehetmann M., Allweiss L., Warlich M., Bierwolf J., Pollok J.M., Petersen J., Matthes E., Dandri M. Strong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice. Antivir. Ther. 2012, 17:623-631.
84. Volz T., Allweiss L., MB M.B., Warlich M., Lohse A.W., Pollok J.M., Alexandrov A., Urban S., Petersen J., Lutgehetmann M., Dandri M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J. Hepatol. 2013, 58:861-867.
85. von Weizsacker F., Kock J., MacNelly S., Ren S., Blum H.E., Nassal M. The tupaia model for the study of hepatitis B virus: direct infection and HBV genome transduction of primary tupaia hepatocytes. Methods Mol. Med. 2004, 96:153-161.
86. Walter E., Keist R., Niederost B., Pult I., Blum H.E. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 1996, 24:1-5.
87. Washburn M.L., Bility M.T., Zhang L., Kovalev G.I., Buntzman A., Frelinger J.A., Barry W., Ploss A., Rice C.M., Su L. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011, 140:1334-1344.
88. Watanabe T., Tanigawa T., Shiba M., Nadatani Y., Nagami Y., Sugimori S., Yamagami H., Watanabe K., Tominaga K., Fujiwara Y., Koike T., Arakawa T. Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients. Gut 2014 Mar, 63(3):409-414.
89. Weber O., Schlemmer K.H., Hartmann E., Hagelschuer I., Paessens A., Graef E., Deres K., Goldmann S., Niewoehner U., Stoltefuss J., Haebich D., Ruebsamen-Waigmann H., Wohlfeil S. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antivir. Res. 2002, 54:69-78.
90. Wieland S.F., Vega R.G., Muller R., Evans C.F., Hilbush B., Guidotti L.G., Sutcliffe J.G., Schultz P.G., Chisari F.V. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J. Virol. 2003, 77:1227-1236.
91. Yan H., Zhong G., Xu G., He W., Jing Z., Gao Z., Huang Y., Qi Y., Peng B., Wang H., Fu L., Song M., Chen P., Gao W., Ren B., Sun Y., Cai T., Feng X., Sui J., Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012, 1:e00049.
92. Yan H., Peng B., He W., Zhong G., Qi Y., Ren B., Gao Z., Jing Z., Song M., Xu G., Sui J., Li W. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J. Virol. 2013, 87:7977-7991.
93. Yang P.L., Althage A., Chung J., Chisari F.V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13825-13830.
94. Zoulim F., Saputelli J., Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J. Virol. 1994, 68:2026-2030.